Effects of pravastatin on lipoproteins and endothelial function in patients receiving human immunodeficiency virus protease inhibitors

This publication has 30 references indexed in Scilit:

• Guidelines for the Evaluation and Management of Dyslipidemia in Human Immunodeficiency Virus (HIV)-Infected Adults Receiving Antiretroviral Therapy: Recommendations of the HIV Medicine Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group
  Clinical Infectious Diseases, 2003
• Protease inhibitors and cardiovascular outcomes in patients with HIV-1
  The Lancet, 2002
• Dietary advice with or without pravastatin for the management of hypercholesterolaemia associated with protease inhibitor therapy
  AIDS, 2001
• Use of Human Immunodeficiency Virus-1 Protease Inhibitors Is Associated With Atherogenic Lipoprotein Changes and Endothelial Dysfunction
  Circulation, 2001
• Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects
  AIDS, 2000
• Hyperlipidemia and Insulin Resistance Are Induced by Protease Inhibitors Independent of Changes in Body Composition in Patients With HIV Infection
  JAIDS Journal of Acquired Immune Deficiency Syndromes, 2000
• Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors
  AIDS, 1999
• A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors
  AIDS, 1998
• HIV-Protease Inhibitors
  New England Journal of Medicine, 1998
• Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
  New England Journal of Medicine, 1995